Shaker Investments LLC OH Has $4.50 Million Stock Position in iRadimed Corporation $IRMD

Shaker Investments LLC OH raised its holdings in shares of iRadimed Corporation (NASDAQ:IRMD) by 18.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,199 shares of the medical equipment provider’s stock after purchasing an additional 10,056 shares during the period. iRadimed accounts for approximately 1.8% of Shaker Investments LLC OH’s holdings, making the stock its 15th biggest holding. Shaker Investments LLC OH owned about 0.50% of iRadimed worth $4,497,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Jump Financial LLC raised its stake in shares of iRadimed by 4.9% during the first quarter. Jump Financial LLC now owns 4,300 shares of the medical equipment provider’s stock worth $226,000 after buying an additional 200 shares during the last quarter. CWM LLC raised its position in shares of iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares during the last quarter. State of Wyoming lifted its stake in shares of iRadimed by 11.3% in the 1st quarter. State of Wyoming now owns 3,013 shares of the medical equipment provider’s stock valued at $158,000 after purchasing an additional 307 shares during the period. Finally, Hsbc Holdings PLC boosted its position in shares of iRadimed by 3.4% in the 1st quarter. Hsbc Holdings PLC now owns 11,912 shares of the medical equipment provider’s stock worth $614,000 after purchasing an additional 392 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Price Performance

NASDAQ:IRMD opened at $97.45 on Friday. The business’s 50-day simple moving average is $88.72 and its 200-day simple moving average is $74.24. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $98.44. The stock has a market capitalization of $1.24 billion, a PE ratio of 59.06 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently announced a special dividend, which will be paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio is presently 41.21%.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $96.73, for a total value of $483,650.00. Following the sale, the chief executive officer owned 2,287,500 shares of the company’s stock, valued at $221,269,875. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the transaction, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 65,000 shares of company stock valued at $5,548,150. Corporate insiders own 36.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Roth Capital set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Zacks Research raised iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital reissued a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research note on Monday, November 3rd. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, iRadimed has a consensus rating of “Moderate Buy” and an average target price of $87.33.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.